Changes in levels of various markers of hemolysis and platelet counts during eculizumab therapy
. | Normal range . | Time of analysis∥ . | . | . | . | ||
|---|---|---|---|---|---|---|---|
| Biochemical marker . | . | Before study† . | 12 wk . | 64 wk . | P* . | ||
| LDH, IU/L | |||||||
| All patients | 150-480 | 3110.7 ± 598.4 | 594.0 ± 31.7 | 622.4 ± 41.1 | .002 | ||
| Patients without cytopenia‡ | NA | 3965.0 ± 971.7 | 617.2 ± 24.3 | 657.1 ± 54.8 | — | ||
| Patients with cytopenia§ | NA | 2085.0 ± 267.0 | 566.3 ± 65.5 | 580.8 ± 63.2 | — | ||
| AST, IU/L | |||||||
| All patients | 10-40 | 76.2 ± 16.0 | 26.2 ± 2.3 | 30.1 ± 3.2 | .02 | ||
| Patients without cytopenia | NA | 88.5 ± 28.3 | 24.4 ± 3.8 | 30.8 ± 5.7 | — | ||
| Patients with cytopenia | NA | 61.4 ± 9.8 | 28.4 ± 2.4 | 29.1 ± 2.3 | — | ||
| Haptoglobin, g/L | |||||||
| All patients | 0.5-2 | 0.06 ± 0 | 0.07 ± .01 | 0.14 ± 0.07 | NS | ||
| Patients without cytopenia | NA | 0.06 ± 0 | 0.08 ± .02 | 0.20 ± 0.12 | — | ||
| Patients with cytopenia | NA | 0.06 ± 0 | 0.06 ± 0 | 0.08 ± 0.01 | — | ||
| Hemoglobin, g/dL | |||||||
| All patients | 11.5-18 | 10.0 ± 0.4 | 10.3 ± 0.4 | 10.4 ± 0.4 | NS | ||
| Patients without cytopenia | NA | 10.4 ± 0.5 | 10.9 ± 0.6 | 10.8 ± 0.5 | — | ||
| Patients with cytopenia | NA | 9.5 ± 0.7 | 9.6 ± 0.4 | 9.9 ± 0.5 | — | ||
| Bilirubin, μM | |||||||
| All patients | 3-15 | 25.9 ± 4.3 | 28.2 ± 4.4 | 28.7 ± 4.0 | NS | ||
| Patients without cytopenia | NA | 30.6 ± 7.4 | 34.9 ± 6.6 | 34.6 ± 5.9 | — | ||
| Patients with cytopenia | NA | 20.2 ± 2.2 | 20.2 ± 3.6 | 21.7 ± 3.6 | — | ||
| Reticulocytes, × 10−3/mm3 | |||||||
| All patients | 20-80 | 161.4 ± 25.9 | 191.2 ± 23.6 | 189.6 ± 21.8 | NS | ||
| Patients without cytopenia | NA | 200.2 ± 38.4 | 243.4 ± 26.2 | 233.2 ± 27.4 | — | ||
| Patients with cytopenia | NA | 114.8 ± 21.9 | 128.5 ± 15.6 | 137.3 ± 15.2 | — | ||
| Platelets, × 109/L | |||||||
| All patients | 150-400 | 183.0 ± 35.3 | 183.6 ± 37.8 | 180.8 ± 35.8 | NS | ||
| Patients without cytopenia | NA | 250.2 ± 49.8 | 256.3 ± 51.8 | 251.5 ± 47.2 | — | ||
| Patients with cytopenia | NA | 102.2 ± 11.8 | 96.3 ± 18.7 | 95.9 ± 19.7 | — | ||
. | Normal range . | Time of analysis∥ . | . | . | . | ||
|---|---|---|---|---|---|---|---|
| Biochemical marker . | . | Before study† . | 12 wk . | 64 wk . | P* . | ||
| LDH, IU/L | |||||||
| All patients | 150-480 | 3110.7 ± 598.4 | 594.0 ± 31.7 | 622.4 ± 41.1 | .002 | ||
| Patients without cytopenia‡ | NA | 3965.0 ± 971.7 | 617.2 ± 24.3 | 657.1 ± 54.8 | — | ||
| Patients with cytopenia§ | NA | 2085.0 ± 267.0 | 566.3 ± 65.5 | 580.8 ± 63.2 | — | ||
| AST, IU/L | |||||||
| All patients | 10-40 | 76.2 ± 16.0 | 26.2 ± 2.3 | 30.1 ± 3.2 | .02 | ||
| Patients without cytopenia | NA | 88.5 ± 28.3 | 24.4 ± 3.8 | 30.8 ± 5.7 | — | ||
| Patients with cytopenia | NA | 61.4 ± 9.8 | 28.4 ± 2.4 | 29.1 ± 2.3 | — | ||
| Haptoglobin, g/L | |||||||
| All patients | 0.5-2 | 0.06 ± 0 | 0.07 ± .01 | 0.14 ± 0.07 | NS | ||
| Patients without cytopenia | NA | 0.06 ± 0 | 0.08 ± .02 | 0.20 ± 0.12 | — | ||
| Patients with cytopenia | NA | 0.06 ± 0 | 0.06 ± 0 | 0.08 ± 0.01 | — | ||
| Hemoglobin, g/dL | |||||||
| All patients | 11.5-18 | 10.0 ± 0.4 | 10.3 ± 0.4 | 10.4 ± 0.4 | NS | ||
| Patients without cytopenia | NA | 10.4 ± 0.5 | 10.9 ± 0.6 | 10.8 ± 0.5 | — | ||
| Patients with cytopenia | NA | 9.5 ± 0.7 | 9.6 ± 0.4 | 9.9 ± 0.5 | — | ||
| Bilirubin, μM | |||||||
| All patients | 3-15 | 25.9 ± 4.3 | 28.2 ± 4.4 | 28.7 ± 4.0 | NS | ||
| Patients without cytopenia | NA | 30.6 ± 7.4 | 34.9 ± 6.6 | 34.6 ± 5.9 | — | ||
| Patients with cytopenia | NA | 20.2 ± 2.2 | 20.2 ± 3.6 | 21.7 ± 3.6 | — | ||
| Reticulocytes, × 10−3/mm3 | |||||||
| All patients | 20-80 | 161.4 ± 25.9 | 191.2 ± 23.6 | 189.6 ± 21.8 | NS | ||
| Patients without cytopenia | NA | 200.2 ± 38.4 | 243.4 ± 26.2 | 233.2 ± 27.4 | — | ||
| Patients with cytopenia | NA | 114.8 ± 21.9 | 128.5 ± 15.6 | 137.3 ± 15.2 | — | ||
| Platelets, × 109/L | |||||||
| All patients | 150-400 | 183.0 ± 35.3 | 183.6 ± 37.8 | 180.8 ± 35.8 | NS | ||
| Patients without cytopenia | NA | 250.2 ± 49.8 | 256.3 ± 51.8 | 251.5 ± 47.2 | — | ||
| Patients with cytopenia | NA | 102.2 ± 11.8 | 96.3 ± 18.7 | 95.9 ± 19.7 | — | ||
— indicates not determined; NA, not applicable; and NS, not significant.
Comparisons of mean change from the prestudy period to the 64-week treatment period for all patients.
Mean values during 52-week period before treatment except for AST, which represents the baseline mean.
Platelet count ≥ 150 × 109/L; n = 6.
Platelet count < 150 × 109/L; n = 5.
Values are presented as ± standard error (SE).